Gastrointestinal disease drug developer Phathom raised almost $182m in an initial public offering that involved Takeda bumping up its equity stake in the company.

US-based gastrointestinal disease therapy developer Phathom Pharmaceuticals went public on Friday in an initial public offering sized at approximately $182m while pharmaceutical firm Takeda boosted its stake. The company increased the number of shares in the offering from 7.9 million to approximately 9.56 million and priced them at $19.00 each, in the middle of the…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.